Authored By: Sarah
11 Jul 2024

 Colorectal Cancer Therapeutics Market Size to grow by USD 2001.8 million between 2024-2028

According to a research report “ Colorectal Cancer Therapeutics Market” by Type (Targeted therapy, Immunotherapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 2001.8 million, at a CAGR of  4.5% during the forecast period. The aging population represents a significant risk factor for colorectal cancer, with over 90% of cases reported by the CDC occurring in individuals aged 50 and above. According to the World Bank and NIH, the global geriatric population is projected to expand from 9.3% in 2020 to approximately 17% by 2050. The US Census Bureau forecasts a corresponding increase in the population aged 65 and above to 1,566 million by 2050. This demographic shift is expected to lead to a corresponding rise in colorectal cancer cases, thereby fueling market growth for related therapeutics.

Browse market data tables, figures, and in-depth TOC on “Colorectal Cancer Therapeutics Market” by Type (Targeted therapy, Immunotherapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Type, the Targeted therapy segment is projected to dominate the market size in 2024


By Geography, North America  segment is expected to hold the largest market size for the year 2024

The colorectal cancer therapeutics market represents a significant business opportunity due to the rising prevalence of this disease and the continuous development of innovative treatments. Key players are focusing on advancing targeted therapies and immunotherapies to improve patient outcomes. The market is expected to grow steadily, driven by increasing research and development investments and expanding patient populations. Companies must stay abreast of regulatory requirements and competitive landscape to maintain market share.

North America is forecasted to hold the largest market size by region in 2024

The colorectal cancer therapeutics market represents a significant business opportunity due to the increasing global burden of this disease. With a growing aging population and rising incidences of colorectal cancer, there is a pressing need for innovative and effective therapeutic solutions. Key players in this market are investing heavily in research and development to bring novel treatments to market, leveraging advanced technologies and targeted therapies to improve patient outcomes. The market is expected to grow robustly over the forecast period, driven by these trends and increasing healthcare spending.

The Colorectal Cancer Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Accord Healthcare Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Biocon Ltd.
  • Bristol Myers Squibb Co.
  • CK Hutchison Holdings Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • Hetero Drugs Ltd.
  • Hikma Pharmaceuticals Plc
  • Merck and Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Colorectal cancer is a significant health concern worldwide, with incident cases and diagnosis rates on the rise, particularly in the aging population. Companies like Genentech and MSD are leading the charge in colorectal cancer therapeutics with their innovative offerings. Genentech's Tecentriq and MSD's Keytruda are revolutionizing oncology with their immunotherapies, targeting specific proteins like tyrosine kinase. However, the patent expiries of key drugs like Avastin, Erbitux, and Stivarga, which are used in chemotherapy, targeted therapy, and immunotherapy, may impact market dynamics. Oncology Analyst Thomas Wales predicts an increasing trend towards online, retail, and hospital pharmacies as patients seek greater convenience and affordability. YoungOnset Colorectal Cancer and gastrointestinal carcinoid are emerging areas of focus, with institutions like Dana-Farber leading research efforts. KRAS mutation testing is also gaining importance in personalized treatment plans. As the colorectal cancer landscape evolves, the role of targeted therapies in managing colorectal adenocarcinoma and colorectal cancer remains a critical area of investigation.

Market Research Overview

Colorectal cancer (CRC) is a significant global health issue with an estimated 1.9 million incident cases and 935,000 deaths in 2020. The unmet need for effective treatments, especially for NRAS mutants and microsatellite instability-positive tumors, is driving the colorectal cancer therapeutics market. Biomarkers play a crucial role in identifying patients who will benefit from targeted therapies, such as Lumakras from Mirati Therapeutics for KRAS mutations or Tecentriq from Genentech for PD-L1 expression. However, challenges like discontinuation due to serious adverse events and tolerability issues persist. Chemotherapies containing FOLFOX, FOLFIRI, and capecitabine remain the mainstay of treatment, but the regulatory scenario is evolving with the approval of new drugs like Krazati (Hutchmed) for refractory metastatic CRC and Fruquintinib (Akeda) for metastatic CRC in China. Immunotherapies, such as Tecentriq, Keytruda, and Avastin, are gaining popularity due to their efficacy and improved tolerability. The pipeline analysis reveals several promising drugs, including Cotellic (Roche) for BRAF V600E mutations and BRAFTOVI (MSD) for BRAF V600E and V600K mutations. The market landscape is also influenced by patent expiries, biosimilars, and the availability of drugs through various channels, including online, retail, and hospital pharmacies. YoungOnset Colorectal Cancer research at Dana-Farber and gastrointestinal carcinoid research are some of the emerging areas in CRC research. The aging population and the need for early diagnosis through mutation testing continue to be significant challenges. (Source: Oncology Analyst, Thomas Wales)


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!